title: Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
abstract: Weight loss, regular exercise, and diet composition modification seem to improve biochemical and histologic abnormalities. Other therapies directed at insulin resistance, oxidative stress, cytoprotection, and fibrosis may also offer benefits. Insulin sensitizers and vitamin E seem to be the most promising; however, they cause side effects. A multifaceted approach of lifestyle modifications, weight loss, and pharmacotherapy can be used in combination, but no single treatment approach has proved universally applicable to the general population with nonalcoholic steatohepatitis (NASH). Continuous clinical and preclinical studies on existing and potential drugs are needed to improve treatment of nonalcoholic fatty liver disease/NASH.
authors.affiliation: Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Presbyterian, M2, C-Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA. Electronic address: ganesx@upmc.edu.
authors.forename: Swaytha
authors.initials: S
authors.lastname: Ganesh
authors.affiliation: Liver Transplantation, The Thomas Starzl Transplant Institute, UPMC Montefiore, Room N758.1, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.
authors.forename: Vinod K
authors.initials: VK
authors.lastname: Rustgi
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D063387:Cannabinoid Receptor Antagonists / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D007783:Lactones / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000628:therapy; D000077403:Orlistat; D010431:Pentoxifylline / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D000077285:Rimonabant; D058616:Synbiotics; D045162:Thiazolidinediones / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D057911:Angiotensin Receptor Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019440:Anti-Obesity Agents; D000924:Anticholesteremic Agents; D000975:Antioxidants; D063387:Cannabinoid Receptor Antagonists; D002756:Cholagogues and Choleretics; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D007783:Lactones; D010880:Piperidines; D011720:Pyrazoles; D045162:Thiazolidinediones; D014810:Vitamin E; D014580:Ursodeoxycholic Acid; D008687:Metformin; D000077403:Orlistat; D000077285:Rimonabant; D010431:Pentoxifylline; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: Antioxidants; Fatty acids; Insulin sensitizers; Lifestyle modification; NASH; Pharmacologic therapy; Weight loss